Isofol Medical AB (publ) (ISOFOL.ST)
SEK 2.53
(3.06%)
SEK 2.53
(3.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 721 Thousand SEK | -94.37% |
| 2022 | 12.79 Million SEK | -42.89% |
| 2021 | 22.4 Million SEK | -39.63% |
| 2020 | 37.11 Million SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | -100.0% |
| 2017 | 227 Thousand SEK | -55.31% |
| 2016 | 508 Thousand SEK | 171.66% |
| 2015 | 187 Thousand SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | 0.0% |
| 2023 Q4 | - SEK | 100.0% |
| 2023 FY | 721 Thousand SEK | -94.37% |
| 2023 Q1 | 721 Thousand SEK | -61.15% |
| 2023 Q2 | 361 Thousand SEK | -49.93% |
| 2023 Q3 | -1000.00 SEK | -100.28% |
| 2022 Q2 | 4.02 Million SEK | 0.52% |
| 2022 FY | 12.79 Million SEK | -42.89% |
| 2022 Q1 | 4 Million SEK | -14.86% |
| 2022 Q4 | 1.85 Million SEK | -36.15% |
| 2022 Q3 | 2.9 Million SEK | -27.81% |
| 2021 Q4 | 4.7 Million SEK | -8.71% |
| 2021 FY | 22.4 Million SEK | -39.63% |
| 2021 Q1 | 5.21 Million SEK | -72.08% |
| 2021 Q2 | 7.33 Million SEK | 40.61% |
| 2021 Q3 | 5.15 Million SEK | -29.71% |
| 2020 Q3 | 18.43 Million SEK | 0.0% |
| 2020 Q4 | 18.68 Million SEK | 1.31% |
| 2020 FY | 37.11 Million SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | -100.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q3 | 65 Thousand SEK | 0.0% |
| 2017 FY | 227 Thousand SEK | -55.31% |
| 2017 Q1 | 76 Thousand SEK | -6.17% |
| 2017 Q2 | 65 Thousand SEK | -14.47% |
| 2017 Q4 | 21 Thousand SEK | -67.69% |
| 2016 Q4 | 81 Thousand SEK | -10.0% |
| 2016 Q1 | 198 Thousand SEK | 0.0% |
| 2016 FY | 508 Thousand SEK | 171.66% |
| 2016 Q2 | 139 Thousand SEK | -29.8% |
| 2016 Q3 | 90 Thousand SEK | -35.25% |
| 2015 FY | 187 Thousand SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 98.759% |
| Ziccum AB (publ) | 3.74 Million SEK | 80.758% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.883% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 98.572% |
| Mendus AB (publ) | 28.48 Million SEK | 97.469% |
| Genovis AB (publ.) | 158.23 Million SEK | 99.544% |
| Intervacc AB (publ) | 8.01 Million SEK | 91.004% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 83.516% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 99.577% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 98.357% |
| Aptahem AB (publ) | 2.63 Million SEK | 72.592% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | 30.338% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -836.364% |
| Fluicell AB (publ) | 3.33 Million SEK | 78.4% |
| Saniona AB (publ) | 16.84 Million SEK | 95.719% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 95.606% |
| Biovica International AB (publ) | 7.29 Million SEK | 90.11% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | 40.067% |
| AcouSort AB (publ) | 10.55 Million SEK | 93.167% |
| Xintela AB (publ) | 78 Thousand SEK | -824.359% |
| Abliva AB (publ) | 137 Thousand SEK | -426.277% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 98.748% |
| Karolinska Development AB (publ) | 2.01 Million SEK | 64.201% |
| OncoZenge AB (publ) | 3000.00 SEK | -23933.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -365.161% |
| CombiGene AB (publ) | 5.54 Million SEK | 86.995% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.94% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.958% |
| Corline Biomedical AB | 25.03 Million SEK | 97.119% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 87.302% |
| I-Tech AB | 120.86 Million SEK | 99.403% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 99.462% |
| Cyxone AB (publ) | 5.14 Million SEK | 85.995% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 89.773% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 93.239% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 93.58% |
| Nanologica AB (publ) | 1.44 Million SEK | 50.035% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -1260.377% |
| BioInvent International AB (publ) | 71.46 Million SEK | 98.991% |
| Alzinova AB (publ) | 270 Thousand SEK | -167.037% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 97.953% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 50.718% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | 74.451% |
| Simris Alg AB (publ) | 4.35 Million SEK | 83.441% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -454.615% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 99.698% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -3034.783% |